National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedRhee TG, Kumar M, Ross JS
Age-related trajectories of cardiovascular risk and use of aspirin and statin among U.S. Adults Aged 50 or older, 2011-2018.
The purpose of this study was to examine age-related trajectories of cardiovascular risk and use of aspirin and statin among U.S. adults aged 50 or older. The investigators concluded that while adults aged ≥75 do not benefit from the use of aspirin to prevent the first CVD, many continue to take aspirin on a regular basis. In spite of the clear benefit of statin use to prevent a subsequent CVD event, many older adults in this risk category are not taking a statin.
AHRQ-funded; HS022882.
Citation: Rhee TG, Kumar M, Ross JS .
Age-related trajectories of cardiovascular risk and use of aspirin and statin among U.S. Adults Aged 50 or older, 2011-2018.
J Am Geriatr Soc 2021 May;69(5):1272-82. doi: 10.1111/jgs.17038..
Keywords: Elderly, Blood Thinners, Cardiovascular Conditions, Heart Disease and Health, Risk, Medication
Flory JH, Ukena JK, Floyd JS
Novel anti-glycemic drugs and reduction of cardiovascular risk in diabetes: expectations realized, promises unmet.
The researchers review evidence on cardiovascular risks and benefits of new treatments for type 2 diabetes mellitus. Their review reports new evidence suggesting that the newest diabetes drugs are safe from a cardiovascular perspective. Evidence on benefit from at least some members of the GLP-1 receptor agonist and SGLT-2 inhibitor classes is encouraging but not yet decisive.
AHRQ-funded; HS023898.
Citation: Flory JH, Ukena JK, Floyd JS .
Novel anti-glycemic drugs and reduction of cardiovascular risk in diabetes: expectations realized, promises unmet.
Curr Atheroscler Rep 2016 Dec;18(12):79. doi: 10.1007/s11883-016-0633-y.
.
.
Keywords: Patient-Centered Outcomes Research, Medication, Diabetes, Cardiovascular Conditions, Risk
Guirguis-Blake JM, Evans CV, Senger CA
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
This is an update of a systematic review about the benefits of aspirin for the primary prevention of cardiovascular events in adults aged 40 years or older and to evaluate effect modification in subpopulations. It concluded that the beneficial effect of aspirin for the primary prevention of CVD is modest and also occurs at doses of 100 mg or less per day. Older adults seem to achieve a greater relative MI benefit.
AHRQ-funded; 290201200015.
Citation: Guirguis-Blake JM, Evans CV, Senger CA .
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
Ann Intern Med 2016 Jun 21;164(12):804-13. doi: 10.7326/m15-2113.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Cardiovascular Conditions, Medication, Risk, Prevention